Cargando…
Traitement de la neuromyélite optique de Devic durant de la grossesse
Neuromyelitis optica (Devic’s disease) is an inflammatory demyelinating disease of the central nervous system that mainly affects spinal cord, optic nerve and brain regions with high aquaporin 4 antigen expression. This is a severe autoimmune disease caused by autoantibodies directed against aquapor...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The African Field Epidemiology Network
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075488/ https://www.ncbi.nlm.nih.gov/pubmed/27800085 http://dx.doi.org/10.11604/pamj.2016.24.230.9167 |
_version_ | 1782461875686998016 |
---|---|
author | Daouda, Moussa Toudou Obenda, Norlin Samuel Assadeck, Hamid Camara, Diankanagbe Djibo, Fatimata Hassane |
author_facet | Daouda, Moussa Toudou Obenda, Norlin Samuel Assadeck, Hamid Camara, Diankanagbe Djibo, Fatimata Hassane |
author_sort | Daouda, Moussa Toudou |
collection | PubMed |
description | Neuromyelitis optica (Devic’s disease) is an inflammatory demyelinating disease of the central nervous system that mainly affects spinal cord, optic nerve and brain regions with high aquaporin 4 antigen expression. This is a severe autoimmune disease caused by autoantibodies directed against aquaporin 4 and associated with high morbidity and mortality. Unlike other inflammatory conditions such as multiple sclerosis or rheumatoid polyarthritis, pregnancy does not seem to influence the activity of neuromyelitis optica, hence the need for a thorough treatment during pregnancy. Corticosteroid therapy is the treatment of choice for neuromyelitis optica during pregnancy. Other treatments may also be used including rituximab, some immunosuppressive agents and immunoglobulins. Immunosuppressive treatment or rituximab is recommended when the long-term corticosteroid treatment is contraindicated, in case of inefficiency or if side effects are intolerable. Immunoglobulins are administered to patients with serious outbreaks of neuromyelitis optica which do not respond to bolus methylprednisolone. Immunoglobulins alone can also be continued at a dose of 0.4 g/kg/day for 6-8 weeks until delivery. Plasmapheresis is also a good alternative to bolus methylprednisolone when outbreaks are extremely severe. |
format | Online Article Text |
id | pubmed-5075488 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | The African Field Epidemiology Network |
record_format | MEDLINE/PubMed |
spelling | pubmed-50754882016-10-31 Traitement de la neuromyélite optique de Devic durant de la grossesse Daouda, Moussa Toudou Obenda, Norlin Samuel Assadeck, Hamid Camara, Diankanagbe Djibo, Fatimata Hassane Pan Afr Med J Review Neuromyelitis optica (Devic’s disease) is an inflammatory demyelinating disease of the central nervous system that mainly affects spinal cord, optic nerve and brain regions with high aquaporin 4 antigen expression. This is a severe autoimmune disease caused by autoantibodies directed against aquaporin 4 and associated with high morbidity and mortality. Unlike other inflammatory conditions such as multiple sclerosis or rheumatoid polyarthritis, pregnancy does not seem to influence the activity of neuromyelitis optica, hence the need for a thorough treatment during pregnancy. Corticosteroid therapy is the treatment of choice for neuromyelitis optica during pregnancy. Other treatments may also be used including rituximab, some immunosuppressive agents and immunoglobulins. Immunosuppressive treatment or rituximab is recommended when the long-term corticosteroid treatment is contraindicated, in case of inefficiency or if side effects are intolerable. Immunoglobulins are administered to patients with serious outbreaks of neuromyelitis optica which do not respond to bolus methylprednisolone. Immunoglobulins alone can also be continued at a dose of 0.4 g/kg/day for 6-8 weeks until delivery. Plasmapheresis is also a good alternative to bolus methylprednisolone when outbreaks are extremely severe. The African Field Epidemiology Network 2016-07-13 /pmc/articles/PMC5075488/ /pubmed/27800085 http://dx.doi.org/10.11604/pamj.2016.24.230.9167 Text en © Moussa Toudou Daouda et al. http://creativecommons.org/licenses/by/2.0/ The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Daouda, Moussa Toudou Obenda, Norlin Samuel Assadeck, Hamid Camara, Diankanagbe Djibo, Fatimata Hassane Traitement de la neuromyélite optique de Devic durant de la grossesse |
title | Traitement de la neuromyélite optique de Devic durant de la grossesse |
title_full | Traitement de la neuromyélite optique de Devic durant de la grossesse |
title_fullStr | Traitement de la neuromyélite optique de Devic durant de la grossesse |
title_full_unstemmed | Traitement de la neuromyélite optique de Devic durant de la grossesse |
title_short | Traitement de la neuromyélite optique de Devic durant de la grossesse |
title_sort | traitement de la neuromyélite optique de devic durant de la grossesse |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075488/ https://www.ncbi.nlm.nih.gov/pubmed/27800085 http://dx.doi.org/10.11604/pamj.2016.24.230.9167 |
work_keys_str_mv | AT daoudamoussatoudou traitementdelaneuromyeliteoptiquededevicdurantdelagrossesse AT obendanorlinsamuel traitementdelaneuromyeliteoptiquededevicdurantdelagrossesse AT assadeckhamid traitementdelaneuromyeliteoptiquededevicdurantdelagrossesse AT camaradiankanagbe traitementdelaneuromyeliteoptiquededevicdurantdelagrossesse AT djibofatimatahassane traitementdelaneuromyeliteoptiquededevicdurantdelagrossesse |